β,β,β,-trichloroethylchloroformate | 57691-12-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: β,β,β,-trichloroethylchloroformate
• 英文别名: Monochloroacetic acid 2,2,2-trichloroethyl ester；2,2,2-trichloroethyl monochloroacetate；chloro-acetic acid-(2,2,2-trichloro-ethyl ester)；Chlor-essigsaeure-(2,2,2-trichlor-aethylester)；2,2,2-trichloroethyl chloroacetate；Chlor-essigsaeure-<2.2.2-trichlor-aethylester>；Acetic acid, chloro-, 2,2,2-trichloroethyl ester；2,2,2-trichloroethyl 2-chloroacetate
• CAS: 57691-12-0
• 化学式: C₄H₄Cl₄O₂
• 分子量: 225.887
• InChiKey: YGMJDNNRTOLYEH-UHFFFAOYSA-N

物化性质

• 沸点：
  292.6±35.0 °C(Predicted)
• 密度：
  1.572±0.06 g/cm3(Predicted)
• 保留指数：
  1227

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  β,β,β,-trichloroethylchloroformate 、 甲基 4-O-BETA-D-半乳糖基-BETA-D-吡喃葡萄糖苷 在 subtilisin (Protease N) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 120.0h， 以29%的产率得到methyl 6'-O-monochloroacetyl-β-lactoside
  参考文献：
  名称：

  Application of protease-catalyzed regioselective esterification in synthesis of 6'-deoxy-6'-fluoro- and 6-deoxy-6-fluorolactosides

  摘要：

  Subtilisin-catalyzed esterification of methyl 4-O-beta-D-galactopyranosyl-beta-D-glucopyranoside (methyl beta-lactoside) (1) with 2,2,2-trichloroethyl butyrate (3) distinguished between the two primary hydroxyl groups of 1, yielding exclusively the 6'-O-monobutyryl derivative 6 from which 6'-deoxy-6'-fluoro- and 6-deoxy-6-fluorolactosides (22 and 29, respectively) were efficiently synthesized. A key feature in the synthesis of 22 was the use of the 2,4,6-trimethylbenzoyl (mesitoyl) group to protect the remaining free hydroxyl groups. A mesitoate ester, in addition to being inert to the condition that hydrolyzed a butyrate ester, could be easily cleaved by reduction with AlH3 without hydrogenolysis of a C-F bond. The steric bulk of a mesitoyl group suppressed the C-4' --> C-6' acyl migration during the fluorination with (diethylamino)sulfur trifluoride (DAST). The success in the synthesis of 29 depended on the choice of solvent employed for the DAST fluorination. With diglyme the desired 6-fluoro derivative 28 was the only product, whereas the use of CH2Cl2 yielded 6-O-methyl-beta-lactosyl fluoride 30 concomitantly through a C-1 --> C-6 migration of the methoxyl group.

  DOI：

  10.1021/jo00038a036
• 作为产物：
  描述：

  2,2,2-三氯乙醇 、 氯乙酰氯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 生成 β,β,β,-trichloroethylchloroformate
  参考文献：
  名称：

  Theil, Fritz; Schick, Hans; Lapitskaya, Margarita A., Liebigs Annalen der Chemie, 1991, # 3, p. 195 - 200

  摘要：

  DOI：

文献信息

• Synthesis of strychnine and the Wieland-Gumlich aldehyde
  作者：Philip Magnus、Melvyn Giles、Roger Bonnert、Gary Johnson、Leslie McQuire、Mark Deluca、Andrew Merritt、Chung S. Kim、Nigel Vicker

  DOI：10.1021/ja00071a025

  日期：1993.9

  with (phenylthio)acetic acid activated by bis(2-oxo-3-oxazolidinyl)phosphinic acid to give amide 15. Treatment of 15 with sodium hydride in tetrahydrofuran at 25 o C resulted in rapid conversion into a single diastereomer, 16. This same conjugate addition has been conducted at the sulfoxide oxidation level and also with a chiral sulfoxide to provide optically active compounds (Scheme VI). Conversion

  四环胺 9 通过几个步骤转化为仲胺 13 并用由双（2-氧代-3-恶唑烷基）次膦酸活化的（苯硫基）乙酸乙酰化，得到酰胺 15。 15 在四氢呋喃中用氢化钠处理 25 o C 导致快速转化为单一的非对映异构体，16。在亚砜氧化水平下进行相同的共轭加成，并且还与手性亚砜一起进行，以提供旋光化合物（方案 VI）。亚砜 19 转化为二酮 27，然后缩酮化和还原得到叔胺 34。用乙酸汞去保护和氧化得到核心的士的宁骨架 36。36 中的 β-氨基丙烯酸酯双键被还原得到 39，然后差向异构化得到 40。酯40被保护为磺酰胺衍生物44，将酯还原得到 45。醇 45 经正常酸水解得到半缩酮 47。 Wieland-Gumlich 醛 48 通过方案 XI 所示的路线转化为中继化合物，从而提供了一个方便的关联和短路线到 47 . Hemiketal 47 转化为酮 52 并在 25°C 下用 (EtO) 2 P(O)CH
• 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04423213A1

  公开（公告）日：1983-12-27

  The invention relates to novel 7-acylamino-3-vinylcephalosporanic acid derivatives of antimicrobial activity, and to methods of preparation thereof from novel intermediate compounds of the formula: ##STR1## in which R.sub.C is amino or a group of the formula: ##STR2## wherein R.sup.8 is aryl, A.sup.12 is lower alkylene having a group of the formula: .dbd.N.about.OR.sup.4, wherein R.sup.4 is hydrogen, cyclo(lower) alkenyl, lower alkynyl, lower alkenyl, lower alkenyl substituted by carboxy or a protected carboxy group, lower alkyl, or lower alkyl substituted by one or more substituent(s) selected from carboxy, a protected carboxy group, amino, a protected amino group, cyano, phosphono, a protected phosphono group and a heterocyclic group which may have suitable substituent(s), R.sup.a is a protected amino group, R.sup.b is a protected carboxy group, R.sup.c and R.sup.d are combined to form oxo or a protected oxo group, and X.sup.1 is halogen, and R.sup.2 is carboxy or a protected carboxy group, provided that, when R.sub.C is amino, then R.sup.2 is carboxy, or a salt thereof.

  该发明涉及具有抗微生物活性的新型7-酰氨基-3-乙烯头霉素酸衍生物，以及从新型中间化合物制备它们的方法。公式为：其中R.sub.C是氨基或具有以下式的基团：其中R.sup.8是芳基，A.sup.12是具有以下式的低烷基：.dbd.N.about.OR.sup.4，其中R.sup.4是氢，环(低)烯基，低炔基，低烯基，低烯基取代的羧基或受保护的羧基，低烷基，或低烷基取代的一个或多个取代基，所选自羧基，受保护的羧基，氨基，受保护的氨基，氰基，磷酸基，受保护的磷酸基和可能具有适当取代基的杂环基，R.sup.a是受保护的氨基基团，R.sup.b是受保护的羧基，R.sup.c和R.sup.d结合形成氧代基或受保护的氧代基，X.sup.1是卤素，R.sup.2是羧基或受保护的羧基，但当R.sub.C是氨基时，R.sup.2是羧基或其盐。
• 7-acylamino-3-vinylcephalosporanic acid derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04731443A1

  公开（公告）日：1988-03-15

  The invention relates to novel intermediates for the preparation of antimicrobial compounds, the intermediate being a compound of the formula: ##STR1## in which R.sup.2 is carboxy or a protected carboxy group, R.sup.8 is 2-hydroxyphenyl and Z is a group of the formula: --CH.dbd.CH.sub.2, --CH.sub.2 --X.sup.2, --CH.sub.2 P.sup.+ (R.sup.7).sub.3.X.sup.3-, --CH.dbd.P(R.sup.7).sub.3 OR--CH.sub.2 OH, wherein X.sup.2 and X.sup.3 are each halogen and R.sup.7 is selected from the group consisting of phenyl, tolyl, xylyl and naphthyl, or a salt thereof.

  本发明涉及一种用于制备抗微生物化合物的新型中间体，该中间体是式子：##STR1## 其中R.sup.2是羧基或保护羧基，R.sup.8是2-羟基苯基，Z是式子：--CH.dbd.CH.sub.2，--CH.sub.2--X.sup.2，--CH.sub.2P.sup.+ (R.sup.7).sub.3.X.sup.3-，--CH.dbd.P(R.sup.7).sub.3OR--CH.sub.2OH，其中X.sup.2和X.sup.3都是卤素，R.sup.7选自苯基，甲苯基，二甲苯基和萘基，或其盐。
• 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04960889A1

  公开（公告）日：1990-10-02

  Amino-pyridinyl and pyrimidinyl intermediates have been synthesized.

  已经合成了氨基吡啶和嘧啶中间体。
• 3-Phosphonium and 3-phosphoranylidenecephems
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04487927A1

  公开（公告）日：1984-12-11

  This invention relates to novel 7-acylamino-3-vinylcephalosporanic acid derivatives of high antimicrobial activity, to processes for preparation thereof from novel intermediates, and to said intermediates of the formula: ##STR1## in which R.sub.A is a group of the formula: ##STR2## wherein R.sup.1 is amino-substituted-heterocyclic group which may have halogen, protected amino-substituted-heterocyclic group which may have halogen, or a group of the formula: ##STR3## wherein R.sup.3 is lower alkyl, R.sup.8 is aryl, A is lower alkylene which may have a substituent selected from the group consisting of amino, a protected amino group, hydroxy, oxo and a group of the formula: .dbd.N.about.OR.sup.4, wherein R.sup.4 is hydrogen, cyclo(lower)alkenyl, lower alkynyl, lower alkenyl, lower alkenyl substituted by carboxy or a protected carboxy group, lower alkyl, or lower alkyl substituted by one or more substituent(s) selected from carboxy, a protected carboxy group, amino, a protected amino group, cyano, phosphono, a protected phosphono group and a heterocyclic group which may have suitable substituent(s), R.sup.a is a protected amino group, R.sup.b is a protected carboxy group, R.sub.B is a group of the formula: --CH.sub.2 --X.sup.2, --CH.sub.2 P.sup..sym. (R.sup.7).sub.3 .multidot.X.sup.3.crclbar. or --CH.dbd.P(R.sup.7).sub.3 wherein R.sup.7 is aryl, and X.sup.2 and X.sup.3 are each halogen, and R.sup.2 is carboxy or a protected carboxy group, provided that, when R.sub.A is a group of the formula: R.sup.8 --CH.dbd.N--, wherein R.sup.8 is as defined above, then R.sub.B is a group of the formula: --CH.sub.2 P.sup..sym. (R.sup.7).sub.3 .multidot.X.sup.3.crclbar. or --CH.dbd.P(R.sup.7).sub.3, wherein R.sup.7 and X.sup.3 are each as defined above, or a salt thereof.

  该发明涉及一种新的高抗菌活性的7-酰胺基-3-乙烯基头孢菌素酸衍生物，以及从新的中间体制备它们的过程和该式的中间体：##STR1## 其中R.sub.A是以下式的基团：##STR2## 其中R.sup.1是氨基取代的杂环基团，它可能有卤素，受保护的氨基取代的杂环基团，它可能有卤素，或以下式的基团：##STR3## 其中R.sup.3是较低的烷基，R.sup.8是芳基，A是较低的烷基，它可能有从以下组中选择的取代基：氨基，受保护的氨基基团，羟基，氧代或以下式的基团：.dbd.N.about.OR.sup.4，其中R.sup.4是氢，环(较低)烯基，较低炔基，较低烯基，较低烯基，它被羧基或受保护的羧基基团取代，较低烷基或被一个或多个从羧基，受保护的羧基基团，氨基，受保护的氨基基团，氰基，膦酸基，受保护的膦酸基团和可能有适当取代基团的杂环基团取代，R.sup.a是受保护的氨基基团，R.sup.b是受保护的羧基基团，R.sub.B是以下式的基团：--CH.sub.2 --X.sup.2，--CH.sub.2 P.sup..sym. (R.sup.7).sub.3 .multidot.X.sup.3.crclbar.或--CH.dbd.P(R.sup.7).sub.3，其中R.sup.7是芳基，X.sup.2和X.sup.3分别是卤素，R.sup.2是羧基或受保护的羧基基团，但当R.sub.A是以下式的基团：R.sup.8 --CH.dbd.N--，其中R.sup.8如上所定义时，R.sub.B是以下式的基团：--CH.sub.2 P.sup..sym. (R.sup.7).sub.3 .multidot.X.sup.3.crclbar.或--CH.dbd.P(R.sup.7).sub.3，其中R.sup.7和X.sup.3如上所定义，或其盐。